Want to see USAQ full AI Analyst Report?
Top Page
QHSLab
(OTC:USAQ)
Select Model
Select Model
Rating:66Neutral
Price Target:
$0.50
▲(55.31% Upside)
Action:Reiterated
Date:09/16/26
The score is driven primarily by improving profitability and a de-risked balance sheet, tempered by negative TTM operating/free cash flow that undermines earnings quality. Technicals are moderately supportive with price above key short-term averages and positive MACD, while valuation looks favorable on a low P/E. Recent corporate updates reinforce the operational improvement narrative.
Positive Factors
Revenue and Profitability Turnaround
Revenue has expanded from about $1.41M in 2023 to $3.02M TTM while the company moved from earlier losses to positive net income. The combination of growth and strong gross margin indicates improving commercial traction and provides a foundation for continued operating leverage.
Negative Factors
Negative Operating and Free Cash Flow
Reported profitability is not currently converting into cash, with both operating and free cash flow negative in the latest period. Persistent or repeated weak conversion could reduce funding flexibility, increase reliance on financing, and make the earnings recovery less durable than the income statement suggests.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Turnaround
Revenue has expanded from about $1.41M in 2023 to $3.02M TTM while the company moved from earlier losses to positive net income. The combination of growth and strong gross margin indicates improving commercial traction and provides a foundation for continued operating leverage.
Read all positive factors
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.92M
Dividend YieldN/A
Average Volume (3M)2.70K
Price to Earnings (P/E)9.7
Beta (1Y)1.14
Revenue Growth24.61%
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.05
Shares Outstanding15,032,788
10 Day Avg. Volume1,983
30 Day Avg. Volume2,696
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit2.91
Enterprise Value/Ebitda8.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also devel...
QHSLab Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.02M | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Gross Profit | 2.02M | 1.81M | 1.36M | 793.61K | 619.52K | 670.75K |
| EBITDA | 718.32K | 785.56K | 352.39K | -91.29K | -434.60K | -487.63K |
| Net Income | 524.11K | 457.42K | -259.24K | -468.36K | -996.00K | -770.18K |
Balance Sheet | ||||||
| Total Assets | 1.93M | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Cash, Cash Equivalents and Short-Term Investments | 317.39K | 636.16K | 157.17K | 51.58K | 178.69K | 286.86K |
| Total Debt | 95.55K | 20.00K | 1.72M | 1.78M | 1.68M | 1.30M |
| Total Liabilities | 375.82K | 546.08K | 2.41M | 2.06M | 1.88M | 1.38M |
| Stockholders Equity | 1.56M | 1.62M | -607.76K | -375.62K | 76.25K | 824.07K |
Cash Flow | ||||||
| Free Cash Flow | -107.43K | 178.12K | 142.44K | -159.63K | -388.11K | -509.31K |
| Operating Cash Flow | -107.43K | 178.12K | 142.44K | -159.63K | -350.99K | -354.74K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K |
| Financing Cash Flow | 256.46K | 300.87K | -36.85K | 32.52K | 279.95K | 701.82K |
QHSLab Technical Analysis
Positive
0.32
Price Trends
0.35
Positive
0.35
Positive
0.51
Negative
Market Momentum
0.03
Negative
77.23
Negative
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.32 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.35, and below the 200-day MA of 0.51, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 77.23 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 43 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
QHSLab Peers Comparison
UnderperformOutperform
Sector (51)
USAQ
QHSLab
0.46
0.30
187.50%
NUWE
Nuwellis
0.69
-119.01
-99.42%
AEMD
Aethlon Medical
6.05
-27.70
-82.07%
BBLG
Bone Biologics
0.47
-2.05
-81.47%
QHSLab Corporate Events
Business Operations and StrategyFinancial Disclosures
QHSLab Reports Strong Q2 Growth in ISP Revenue
Positive
Aug 3, 2026
On August 3, 2026, QHSLab reported unaudited results for the second quarter and first half of 2026, highlighting strong growth in its Integrated Service Program revenue and a shift toward a recurring, software-enabled healthcare platform. Manageme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.